VetStem Biopharma, proudly announces former Director of Pall Life Science Animal Health, Jeffrey Schaffer, DVM, as Director of Veterinary Professional Services.
“With over 15 years of experience in the veterinary regenerative medicine field, Dr. Schaffer will be a great addition to our veterinarian lead organization,” said Dr. Alexis Nahama, president and chief commercial officer. “Dr. Schaffer will be responsible for all technical activities in relationship with our veterinary clients. His extensive knowledge of regenerative medicine, including Stem Cell Therapy and PRP, will help to further VetStem’s education and outreach efforts within the veterinary community. Dr. Schaffer will be instrumental in nurturing our local key opinion leader network and helping us implement strong veterinary centric programs that fit our clients’ needs with our currently available autologous services.”
Schaffer obtained his Doctor of Veterinary Medicine at the University of Perugia. He has practiced veterinary medicine at Nassau-Suffolk Vet Hospital, several emergency veterinary hospitals and animal shelters. He also has worked as professor in medical and biological subjects at numerous colleges and universities in New York. He is the author of a range of published studies and he has established relationships with opinion leaders in medical, veterinary research and clinical practice.
“I am very happy to become part of the VetStem Biopharma team and looking forward to working closely with our equine and companion animal veterinarians clients," said Schaffer. "Having the responsibility for technical and scientific support will be both satisfying and exciting.”
VetStem Biopharma is a veterinarian-led company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 10,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem research team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases.” In addition to the company's own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.